MAPT and Mental deterioration: In some of these studies, the highest levels of CCL2 were observed in patients with severe AD, and they correlated with progression of cognitive decline or CSF concentration of Aβ and hyperphosphorylated tau (Corrêa et al. 2011; Lee et al. 2018).